CD274 and non-small cell lung carcinoma: Another ATR inhibitor, ceralasertib (AZD6738), is currently being evaluated in a phase 2 umbrella trial in NSCLC (the HUDSON trial) in patients who progressed on anti-PD-(L)1 therapy (NCT03334617).